Format

Send to

Choose Destination
Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):831-6. doi: 10.1016/j.ijrobp.2008.10.073. Epub 2009 Mar 21.

A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma.

Author information

1
Department of Radiation Oncology, Institute of Clinical Medicine, University of Tsukuba, Tennodai, Tsukuba, Japan.

Abstract

PURPOSE:

To evaluate the efficacy and safety of hypofractionated proton beam therapy for patients with hepatocellular carcinoma (HCC).

METHODS AND MATERIALS:

Between September 2001 and August 2004, 51 patients with HCC greater than 2 cm away from the porta hepatis or gastrointestinal tract were treated with proton beam therapy to 66 Gy-equivalents (GyE) in 10 fractions.

RESULTS:

Overall survival rates were 49.2 and 38.7% at 3 and 5 years after treatment. Local control rates were 94.5 and 87.8% at 3 and 5 years after treatment. Posttreatment serum alpha-fetoprotein values were significantly reduced when compared with pretreatment values (p < 0.0001). Patients experienced only minor acute reactions of Grade 1 or less, and 3 patients experienced late sequelae of Grade 2 or higher. However, there were no treatment-related deaths.

CONCLUSIONS:

Hypofractionated proton beam therapy is safe and well-tolerated by patients with HCC located greater than 2 cm away from the porta hepatis or gastrointestinal tract and may be effective alternative to other modalities.

PMID:
19304408
DOI:
10.1016/j.ijrobp.2008.10.073
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center